Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
Credit: iStock
The UK is witnessing yet another outbreak of meningitis, with one college student dead and two others infected in Berkshire, according to the UK Health Security Agency (UKHSA).
According to the agency, close contacts of those affected are being offered antibiotics as a precautionary measure.
While stressing that the risk to the wider public remains low, the UKHSA confirmed that one case has been identified as Meningitis B (MenB), while further testing is ongoing.
The latest infections come after a small number of meningitis B cases were reported in the Weymouth region in April, followed by a major outbreak in Kent in March that affected more than 30 people and led to the deaths of a sixth-form pupil and a university student.
The young person who died attended The Henley College, according to a local GP surgery.
Authorities are reportedly sharing information about the infection with students and parents at affected schools. The other two cases are believed to be linked to schools in the Reading area. But the officials are yet to disclose the exact link.
Health officials said close contacts of the infected individuals are being offered antibiotics as a precaution.
Read More: Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support
GP surgery, the Hart Surgery, based in Henley-on-Thames, stated that it was in contact with the UKHSA due to the college’s location, adding that the agency was “actively contacting those who may be at risk due to a close association with the student involved.”
However, it said anyone whom the UKHSA has not contacted does not require treatment, and students and staff can continue attending the sixth-form college as usual.
“The number of confirmed cases is very low, so there are currently no plans for a local emergency meningitis vaccination programme,” it added.
Also read: UK Reports Meningitis Outbreak Among School Children: All You Need To Know
Meningitis is a serious medical condition that affects the protective membranes covering the brain and spinal cord, known as the meninges. Fever is often considered one of the classic symptoms, although it may not always be present.
Understanding the symptoms, causes, and treatment options is important for early diagnosis and timely medical care.
“Anyone can get meningitis, and around 300 to 400 cases of meningococcal disease are diagnosed in England every year. It is most common in babies, young children, teenagers, and young adults," said Dr Rachel Mearkle, a consultant in health protection at the UKHSA.
“It needs to be treated quickly, so it is important to know the signs and symptoms. They can appear in any order and may not all be present, so seek rapid medical attention if there is ever any concern," she added.
The expert noted that "meningococcal meningitis requires very close contact to spread, and large outbreaks such as the one recently seen in Kent are thankfully rare."
“Meningococcal disease does not spread easily, and the risk to the wider public remains low.”
Health officials urged the public to remain alert to the warning signs of meningococcal meningitis. Common symptoms include:
“If the disease is suspected, immediate medical attention should be sought, as it can progress rapidly,” the officials said. While antibiotics provide the quickest short-term protection, vaccines offer longer-term protection.
Credit: Canva
Pancreatic cancer has long been one of the toughest challenges in oncology. With a five-year survival rate hovering around 13 per cent and recurrence rates approaching 80 per cent after treatment, the odds have historically been stacked against patients.
However, an experimental drug called daraxonrasib, developed by the US-based late-stage clinical oncology company Revolution Medicines, has shown promise in improving survival rates in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
“For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life,” said Brian M. Wolpin, professor of medicine at Harvard Medical School, and principal investigator for the trial.
Wolpin noted that the study “indicates that daraxonrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy.”
Daraxonrasib is a once-daily oral pill that demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard intravenous chemotherapy.
Daraxonrasib, described as a multi-selective inhibitor of RAS(ON) proteins, is the first investigational drug in a new class of RAS inhibitors designed to target a broad spectrum of cancer-causing RAS mutations.
In the clinical trial, daraxonrasib showed a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy.
The drug was generally well tolerated and showed a manageable safety profile, with no new safety concerns identified.
Daraxonrasib works by blocking KRAS signalling proteins that drive tumor growth.
Pancreatic cancer is considered one of the most RAS-addicted cancers, with more than 90 per cent of patients carrying tumours driven by RAS protein mutations.
Also read: Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic Cancer
The controlled Phase 3 clinical trial evaluated daraxonrasib in patients with previously treated metastatic PDAC.
The trial included patients with pancreatic tumours carrying a wide range of RAS variants, as well as patients without identified RAS mutations.
The results showed that daraxonrasib significantly improved overall survival in patients with previously treated metastatic pancreatic cancer.
Similar RAS-targeting drugs are now being developed by other companies for pancreatic, lung, and colon cancers.
“It’s the beginning, not the end,” said Elizabeth Jaffee in comments to The New York Times.
According to the company, “Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.”
Prior studies with daraxonrasib have shown that rash is the most common side effect, with mouth sores, diarrhea, nausea, and vomiting also common.
Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi
Based on the first interim analysis, all progression-free survival and overall survival results are now considered final.
Revolution Medicines said it plans to submit the data to global regulators, including the US Food and Drug Administration (FDA), as part of a future New Drug Application under a Commissioner’s National Priority Voucher.
The findings are also expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pancreatic cancer typically begins in the ducts of the organ and can rapidly spread from there to the rest of the organ. Early-stage pancreatic tumors do not show up on imaging tests, making this version of the disease difficult to diagnose until it infects other organs.
The prevention and early detection remain vital.
Experts warn that pancreatic cancer often masquerades as common ailments, delaying diagnosis. Here are some early symptoms that should never be ignored:
Credit: iStock
A French woman infected with the deadly hantavirus outbreak linked to the MV Hondius cruise ship is critically ill and is being treated using an artificial lung.
The woman is among the passengers evacuated from Spain’s Canary Islands. According to the World Health Organization (WHO), 11 people have been affected by the rat-borne virus so far, of whom three have died.
A Dutch couple is believed to have been first exposed to the virus while visiting a birdwatching site in Argentina.
The WHO has confirmed that the Andes strain of hantavirus — the only strain known to spread from person to person — is behind the outbreak.
The French passenger, currently hospitalized in Paris, has developed a severe form of the disease that has caused life-threatening lung and heart complications, Dr. Xavier Lescure, an infectious disease specialist at Bichat Hospital, told AP News Agency.
He explained that “the woman is on a life-support device that pumps blood through an artificial lung, providing it with oxygen and returning it to the body. The hope is that the device relieves enough pressure on the lungs and heart to give them some time to recover.”
Lescure described it as “the final stage of supportive care.”
With the evacuation of all passengers and many crew members completed, the MV Hondius is now sailing back to the Netherlands, where it will undergo cleaning and disinfection.
Speaking to HealthandMe, Dr. Amitav Banerjee, professor at DY Patil Vidyapeeth, Pune, and former field epidemiologist in the Indian Armed Forces, said hantavirus does not spread easily from person to person.
Unlike COVID-19, it does not have significant aerosol or pandemic potential. Only certain strains, such as the Andes strain identified in South America, have shown limited person-to-person transmission, usually through very close or intimate contact involving body fluids.
“That is why the husband and wife may both have become infected. Even then, transmission is rare and requires prolonged close exposure. Basic precautions are generally sufficient, and asymptomatic individuals are unlikely to transmit the infection,” he said.
Dr. Amitav added that hantavirus does not have pandemic potential under natural conditions because it spreads poorly between humans and remains largely linked to rodent exposure.
Dr. Jatin Ahuja, Consultant in Infectious Diseases at Indraprastha Apollo Hospital, Delhi, told HealthandMe that the general public has no reason for alarm.
“Hantavirus infections remain rare globally, and awareness about rodent control and early symptom recognition continues to be the most effective approach,” he said.
He recommended simple preventive measures to significantly reduce risk.
“People should avoid sweeping or vacuuming rodent-infested areas directly, as this may spread contaminated particles into the air. Instead, affected areas should be ventilated first and cleaned using disinfectants while wearing gloves and masks. Proper storage of food, sealing entry points for rodents, and maintaining hygiene in homes, warehouses, and workplaces are also important preventive steps,” the expert added.
© 2024 Bennett, Coleman & Company Limited